Apheresis Market By Product Type (Plasmapheresis, Leukapheresis, Erythrocytapheresis, Thrombopheresis), By Technology (Centrifugation, Filtration), By End-User Industry (Hospitals, Blood Banks, Therapeutic Centers, Research Centers), By Application (Therapeutic Apheresis, Blood Donation, Research & Development, Organ Transplantation); Global Insights & Forecast (2024 - 2030)

As per Intent Market Research, the Apheresis Market was valued at USD 2.1 billion in 2023 and will surpass USD 3.9 billion by 2030; growing at a CAGR of 8.9% during 2024 - 2030.

The apheresis market has been evolving rapidly due to its critical role in blood component separation for both therapeutic and donation purposes. Apheresis is a process that involves the removal of specific blood components such as plasma, white blood cells, or platelets, and is extensively used in treating various diseases, such as autoimmune disorders, and in blood donation for transfusions. Over recent years, technological advancements in apheresis devices, including improvements in filtration and centrifugation technologies, have expanded the scope and efficiency of these procedures, driving significant market growth. This market is witnessing growing demand across various segments such as product type, technology, end-user industries, and applications, as healthcare providers increasingly adopt apheresis as part of routine clinical practice.

Plasmapheresis Segment Is Largest Owing to High Demand in Therapeutic Applications

Plasmapheresis, the largest product segment in the apheresis market, is primarily used for therapeutic purposes, especially in the treatment of autoimmune diseases like multiple sclerosis, lupus, and rheumatoid arthritis. This segment dominates due to the growing prevalence of such conditions and the critical role of plasmapheresis in alleviating symptoms and improving patient outcomes. The ability to separate plasma from the blood, remove harmful antibodies, and return the remaining blood components back to the patient has made plasmapheresis a key therapeutic modality. Additionally, plasmapheresis is frequently used in emergency situations to treat conditions like thrombotic thrombocytopenic purpura (TTP), further increasing its demand.

The continuous development of apheresis technologies and the increasing adoption of plasmapheresis in clinical settings are expected to drive further growth in this segment. As healthcare providers continue to see the therapeutic benefits of plasmapheresis, both in hospital and outpatient settings, it is anticipated that this segment will maintain its leadership in the market.

Filtration Technology Is Fastest Growing Due to Its Enhanced Efficiency

In terms of technology, filtration is the fastest-growing segment within the apheresis market, owing to its ability to offer more efficient and selective separation of blood components. Unlike centrifugation, which separates components based on their density, filtration uses membrane filters to separate specific components from whole blood. This method is particularly useful in applications where precise and specific blood components need to be removed or collected, such as in leukapheresis or plateletpheresis. The growth of filtration technology can be attributed to its reduced complexity, lower equipment costs, and the growing demand for more streamlined, cost-effective blood separation technologies.

Furthermore, filtration technology is often considered less labor-intensive and more automated compared to traditional centrifugation, making it increasingly popular in both hospitals and blood banks. The increasing use of filtration in various apheresis applications, including the collection of blood components for transfusion, is expected to continue its upward trajectory in the coming years.

Hospitals Segment Is Largest Due to High Patient Demand for Apheresis Treatments

The hospital sector remains the largest end-user industry in the apheresis market, driven by the increasing number of patients requiring therapeutic apheresis for the treatment of various chronic and acute conditions. Hospitals use apheresis for conditions such as autoimmune disorders, blood disorders, and organ transplantation. With advancements in medical technology and the availability of more effective apheresis equipment, hospitals are increasingly offering apheresis as part of their comprehensive treatment plans.

Hospitals are also adopting apheresis treatments more extensively due to the growing focus on personalized medicine, where targeted therapies like apheresis can significantly improve patient outcomes. The demand for therapeutic apheresis procedures in hospitals is expected to continue growing, particularly in regions with high healthcare infrastructure and advanced medical practices.

Therapeutic Apheresis Segment Is Largest Due to Increasing Incidence of Chronic Diseases

Therapeutic apheresis, the largest application segment in the market, is used to treat a variety of disorders such as autoimmune diseases, organ transplantation rejection, and some types of cancer. The increasing prevalence of chronic diseases such as rheumatoid arthritis, lupus, and kidney diseases is a major factor driving the growth of this segment. Additionally, the advancements in apheresis devices and technology have led to more effective and less invasive procedures, making therapeutic apheresis more accessible to patients.

The demand for therapeutic apheresis has surged as medical professionals recognize the positive impact of removing harmful substances from the bloodstream, thereby enhancing the patient's quality of life. As the global population continues to age, and chronic conditions become more common, the therapeutic apheresis segment is expected to maintain its dominant position in the market.

North America is Largest Region Due to Well-Established Healthcare Infrastructure

North America is currently the largest region in the apheresis market, driven by the presence of well-established healthcare infrastructure, advanced medical technologies, and high patient awareness. The U.S. dominates the region due to its large number of hospitals and healthcare facilities, high prevalence of chronic diseases, and strong emphasis on advanced medical treatments, including apheresis. The region is home to key players in the apheresis market, which further accelerates innovation and the adoption of new technologies.

The high adoption rates of apheresis therapies for chronic diseases, coupled with the increasing number of blood centers and therapeutic centers, will continue to drive market growth in North America. The favorable reimbursement policies and support from government healthcare programs also contribute to the region's dominance.

Competitive Landscape

The apheresis market is highly competitive, with several key players striving to offer innovative and efficient products that meet the growing demand for blood component separation and therapeutic applications. Major companies in the market include Terumo BCT, Fresenius Medical Care, Haemonetics Corporation, Medtronic, and Cerus Corporation. These companies focus on the development of advanced apheresis machines, consumables, and technologies that can perform blood separation more effectively and with greater automation.

Leading players are also engaged in strategic mergers and acquisitions to expand their product portfolios, enter new markets, and enhance their technological capabilities. For instance, Fresenius Medical Care's acquisition of a prominent apheresis device company allowed it to expand its product offerings, while Terumo BCT's continuous product innovations keep it at the forefront of the market. The competition is expected to intensify as companies strive to capture a larger share of the growing therapeutic apheresis market

Recent Developments:

• Fresenius Medical Care announced the launch of a new apheresis device designed to improve patient outcomes in therapeutic plasma exchange.
• Terumo BCT expanded its range of blood collection technologies with an upgraded system that supports a wider variety of apheresis procedures, improving efficiency.
• Haemonetics Corporation reported the approval of its new leukapheresis system, which enhances the yield and quality of white blood cell collection for leukemia patients.
• Medtronic acquired a major blood separation technology company to strengthen its position in the apheresis market, particularly in therapeutic applications.
• Cerus Corporation received regulatory approval for its new pathogen reduction technology, which is integrated into its apheresis platform to reduce transfusion-related infections

List of Leading Companies:

• Terumo BCT
• Fresenius Medical Care AG & Co. KGaA
• Haemonetics Corporation
• Blood Centers of America, Inc.
• Asahi Kasei Corporation
• Cerus Corporation
• Medtronic
• Kawasaki Heavy Industries, Ltd.
• Beckman Coulter (Danaher Corporation)
• Memphis International, Inc.
• Rockwell Medical, Inc.
• The Becton Dickinson and Company (BD)
• JMS Co., Ltd.
• Kraton Polymers, Inc.
• Samsung Medison Co.

Report Scope: